Glaukos: Steep Premium For New Therapies And Growth

Glaukos has seen its stock price rise recently, driven by the company's new therapies and growth prospects.

The company's iDose drug-device combination has been seen as a key driver of growth.

Want to stay up to date with the world events at sea or at home?